SWOG clinical trial number
S0701
A Phase III Randomized Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori
Closed
Phase
Accrual
100%
Published
Abbreviated Title
Gastric Cancer Prevention
Activated
06/16/2009
Closed
06/30/2010
Participants
Limited: Institutions Listed on the Title Page
Research committees
Prevention & Epidemiology
Treatment
clarithromycin
metronidazole
bismuth subsalicylate / subcitrate
tetracycline
lansoprazole
amoxicillin
Eligibility Criteria Expand/Collapse
Step 1: Participant must be between 21-65 years of age; be the only member from their household participating; no known allergies to study drugs; no known medical conditions other than H. pylori that requires antibiotic therapy; no known medical conditions that may limit life expectancy;must discontinue use or alcohol, antacids, PPIs; no antibiotics within last 30 days prior to registration; willing to return for follow-up visits; allow submission of blood. Female participants must not be pregnant or nursing. Step 2 critieria: Positive UBT test; negative pregnancy test if applicable.
Publication Information Expand/Collapse
2013
PMid: PMID23403682 | PMC number: PMC3697935
Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG trial S0701)
PMid: PMID23263777 | PMC number: PMC3645498
2012
Treatment of Helicobacter pylori in Latin America [correspondence; authors' reply]
PMid: PMID21777974 | PMC number: PMC3313469
2011
A randomized trial comparing 14-day triple, 10-day sequential, and 5-day concomitant therapy to eradicate Helicobacter pylori in seven Latin American populations
14-day triple, 5-day concomitant, and 10-day sequential therapies for helicobacter pylori infection in seven Latin American sites: a randomised trial [PMID:21777974;PMC3313469]
Other Clinical Trials
SWOG Clinical Trial Number
S1904
Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)
Research Committee(s)
Prevention & Epidemiology
Breast Cancer
Activated
09/01/2020
Accrual
99%
Open
Phase
SWOG Clinical Trial Number
CTSU/NHLBI-MDS
The National Myelodysplastic Syndromes (MDS) Study
Research Committee(s)
Prevention & Epidemiology
Leukemia
Activated
06/01/2019
Open
Phase